Related Experiment Video
Updated: Aug 29, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy is effective
S Portsmouth1, N Imami, A Pires
1Chelsea and Westminster Hospital, London, UK. simonportsmouth@hotmail.com
Objectives:
Highly active antiretroviral therapy (HAART) has been advocated for the management of primary HIV-1 infection. We investigated the use of a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen in this setting.
Methods:
Twenty-one antiretroviral-naïve individuals with early HIV-1 disease were treated with a combination of efavirenz and Combivir (GlaxoSmithKline, Uxbridge, Middlesex, UK). They were evaluated for immune and lymphocyte function by standard immunological assays.
Results:
The median time to an undetectable HIV-1 viral load was 12 weeks (range 4-36 weeks). CD4 and CD16/56 counts increased during treatment and CD8 counts decreased minimally. The main side-effects observed were transient sleep disturbances (five patients). In addition, we observed a decrease in lymphocyte activation as assessed by CD38 surface expression.
Conclusions:
This study demonstrates that primary HIV-1 infection can be treated with NNRTI-based HAART.
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Cryptococcal Meningitis
Size and Structure of Viral Genomes

